PI3K Cancer Research Results

PI3K, Phosphatidylinositide-3-Kinases: Click to Expand ⟱
Source: HalifaxProj(inhibit) CGL-CS
Type:
Phosphatidylinositol 3-kinase (PtdIns3K or PI3K) is a family of enzymes that play a crucial role in cell signaling pathways, particularly in the regulation of cell growth, survival, and metabolism. The PI3K pathway is one of the most frequently altered pathways in human cancer. Inhibition of the PI3K pathway has been explored as a therapeutic strategy for cancer treatment. Several PI3K inhibitors have been developed and are currently being tested in clinical trials. These inhibitors can target specific components of the pathway, such as PI3K, AKT, or mTOR.

Class I phosphoinositide 3-kinase (PI3K)
Class III PtdIns3K
In contrast to the class III PtdIns3K as a positive regulator of autophagy, class I PI3K-AKT signaling has an opposing effect on the initiation of autophagy.

PI3K inhibitors include:
-Idelalisib , Copanlisib, Alpelisib
-LY294002?
-Wortmannin: potent PI3K inhibitor, has some associated toxicity.
-Quercetin:
-Curcumin
-Resveratrol
-Epigallocatechin Gallate (EGCG)
Scientific Papers found: Click to Expand⟱
1335- AG,    Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, SkBr3
p‑PI3K↓, p‑GS3Kβ↓, p‑Akt↓, p‑mTOR↓,
2593- Api,    Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo
- in-vivo, BC, 4T1
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, MMP↑, ROS↑, p‑PI3K↓, PI3K↓, Akt↓, NRF2↓, AntiTum↑, OS↑,
1525- Ba,  almon,    Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway
- in-vitro, Lung, H1975 - in-vivo, Lung, NA
eff↑, TumCP↓, Apoptosis↑, cl‑Casp3↑, cl‑PARP↑, cl‑Casp9↑, p‑PI3K↓, p‑Akt↓, ROS↑, eff↓,
1102- BBR,    Berberine suppressed epithelial mesenchymal transition through cross-talk regulation of PI3K/AKT and RARα/RARβ in melanoma cells
- in-vitro, Melanoma, B16-BL6
TumCMig↓, TumCI↓, EMT↓, p‑PI3K↓, p‑Akt↓, RARα↓, RARβ↑, RARγ↑, E-cadherin↑, N-cadherin↓,
5639- BCA,    Biochanin A Induces Apoptosis in MCF-7 Breast Cancer Cells through Mitochondrial Pathway and Pi3K/AKT Inhibition
- in-vitro, BC, NA
TumCP↓, ROS↑, Apoptosis↑, Bcl-2↓, p‑PI3K↓, p‑Akt↓, BAX↑, Casp3↑, Casp9↑, Cyt‑c↑, CycD3↓, CycB/CCNB1↓, CDK1↓, CDK2↓, CDK4↓, P21↑, p27↑, P53↑, tumCV↓, PI3K↓, Akt↓,
2757- BetA,    Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways
- in-vitro, GBM, U251
tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, Ferroptosis↑, HO-1↑, NRF2↑,
468- CUR,  5-FU,    Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability
- vitro+vivo, Liver, HepG2 - vitro+vivo, Liver, 402 - vitro+vivo, Liver, Bel7
Apoptosis↑, TumCCA↑, PI3k/Akt/mTOR↓, p‑PI3K↓, Bacteria↑, cl‑Casp3↑,
997- GA,    The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H292 - in-vitro, Nor, HUVECs
PD-L1↓, p‑EGFR↓, p‑PI3K↓, p‑Akt↓, P53↑, miR-34a↑, *toxicity↓,
828- GAR,  Cisplatin,    Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells
- in-vitro, Ovarian, OVCAR-3
tumCV↓, cl‑PARP↑, cl‑Casp3↑, BAX↑, p‑PI3K↓, p‑Akt↓, NF-kB↓,
2521- H2,    Oxyhydrogen Gas: A Promising Therapeutic Approach for Lung, Breast and Colorectal Cancer
- Review, CRC, NA - Review, Lung, NA - Review, BC, NA
Inflam↑, ROS↓, ChemoSen↑, p‑PI3K↓, p‑Akt↓, QoL↑, GutMicro↑, chemoP↑, radioP↑, *NRF2↑, *Catalase↑, *GPx↑, *HO-1↑, *SOD↑, *TNF-α↓, *IL4↓, *IL6↓, ChemoSen↑, Appetite↑, cognitive↑, Pain↓, Sleep↑, other?,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
1126- Lyco,    Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway
- vitro+vivo, Oral, NA
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, PI3K↓, Akt↓, mTOR↓, E-cadherin↓, BAX↑, N-cadherin↓, p‑PI3K↓, p‑Akt↓, p‑mTOR↓, Bcl-2↓,
4535- MAG,  5-FU,    Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways
- in-vitro, Cerv, NA
ChemoSen↑, TumCP↓, vinculin↓, TumCA↓, TumCMig↓, TumCI↓, p‑Akt↓, p‑PI3K↓, mTOR↓, E-cadherin↑, β-catenin/ZEB1↑, Snail↓, Slug↓,
1089- MAG,    Magnolol potently suppressed lipopolysaccharide-induced iNOS and COX-2 expression via downregulating MAPK and NF-κB signaling pathways
- in-vitro, AML, RAW264.7
p‑IκB↓, NF-kB↓, p‑ERK↓, p‑JNK↓, p‑PI3K↓, p‑Akt↓, iNOS↓, COX2↓,
5208- PI,    Piperine Inhibits Cell Proliferation and Induces Apoptosis of Human Gastric Cancer Cells by Downregulating Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway
- in-vitro, GC, SNU16 - in-vitro, Nor, GES-1
TumCP↓, Apoptosis↑, BAX↑, BAD↑, Cyt‑c↑, cl‑PARP↑, cl‑Casp3↑, Bcl-2↓, Bcl-xL↓, p‑PI3K↓, p‑Akt↓, Ki-67↓, toxicity↓, RadioS↑,
61- QC,    Midkine downregulation increases the efficacy of quercetin on prostate cancer stem cell survival and migration through PI3K/AKT and MAPK/ERK pathway
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, ARPE-19
p‑PI3K↓, p‑Akt↓, p‑ERK↓, NF-kB↓, p38↓, ABCG2↓, CD44↓, CD133↓, CSCs↓,
3061- RES,    The Anticancer Effects of Resveratrol: Modulation of Transcription Factors
- Review, Var, NA
AhR↓, NRF2↑, *NQO1↑, *HO-1↑, *GSH↑, P53↑, Cyt‑c↑, Diablo↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, FOXO↑, p‑PI3K↓, p‑Akt↓, BIM↑, DR4↑, DR5↑, p27↑, cycD1/CCND1↓, SIRT1↑, NF-kB↓, ATF3↑,
5076- SSE,    Sodium selenite inhibits the growth of cervical cancer cells through the PI3K/AKT pathway
- in-vivo, Cerv, HeLa - in-vivo, Cerv, SiHa
TumCG↓, toxicity↓, tumCV↓, Apoptosis↑, p‑PI3K↓, p‑Akt↓, eff↑,
1019- TQ,    Thymoquinone suppresses migration of LoVo human colon cancer cells by reducing prostaglandin E2 induced COX-2 activation
- vitro+vivo, CRC, LoVo
TumCP↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, β-catenin/ZEB1↓, COX2↓, PGE2↓, EP2↓, EP4↓,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,
4862- Uro,    Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease
- in-vivo, AD, NA - in-vitro, Nor, PC12
*cognitive↑, *p‑PI3K↓, *p‑Akt↓, *AMPK↑, *VDAC1↓, *neuroP↑, *PARK2↑, *PTEN↑, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p62↓, *Aβ↓, *Apoptosis↓,

Showing Research Papers: 1 to 21 of 21

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 21

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ATF3↑, 1,   Catalase↓, 1,   CYP1A1↓, 1,   Ferroptosis↑, 1,   GPx↓, 1,   GSH↓, 2,   GSR↓, 1,   GSTs↓, 1,   HO-1↓, 1,   HO-1↑, 1,   NQO1↓, 1,   NRF2↓, 2,   NRF2↑, 2,   ROS↓, 1,   ROS↑, 4,   SOD↓, 1,   SOD2↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   MMP↑, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

p‑GS3Kβ↓, 1,   PI3k/Akt/mTOR↓, 1,   RARα↓, 1,   RARβ↑, 1,   RARγ↑, 1,   SIRT1↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

AhR↓, 1,   Akt↓, 3,   p‑Akt↓, 18,   Apoptosis↑, 8,   BAD↑, 1,   BAX↑, 4,   Bcl-2↓, 5,   Bcl-xL↓, 2,   BIM↑, 1,   Casp1↓, 1,   Casp3↑, 2,   cl‑Casp3↑, 4,   Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 4,   Diablo↑, 1,   DR4↑, 1,   DR5↑, 2,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 1,   HGF/c-Met↓, 1,   iNOS↓, 1,   p‑JNK↓, 1,   p‑JNK↑, 1,   MAPK↓, 1,   p‑MDM2↓, 1,   p27↑, 2,   p38↓, 1,   p‑p38↑, 1,   survivin↓, 1,  

Transcription & Epigenetics ⓘ

H3↓, 1,   H4↓, 1,   other?, 1,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   p‑eIF2α↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,   P53↑, 3,   PARP↑, 1,   cl‑PARP↑, 3,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   CycD3↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 1,   CD34↓, 1,   CD44↓, 1,   cFos↑, 1,   CSCs↓, 1,   EMT↓, 4,   EP2↓, 1,   EP4↓, 1,   p‑ERK↓, 2,   FOXO↑, 1,   p‑GSK‐3β↓, 2,   HDAC↓, 2,   miR-34a↑, 1,   mTOR↓, 3,   p‑mTOR↓, 2,   NOTCH1↓, 1,   PI3K↓, 3,   p‑PI3K↓, 20,   PTEN↓, 1,   p‑Src↓, 1,   STAT3↓, 1,   p‑STAT6↓, 1,   TumCG↓, 1,  

Migration ⓘ

AXL↓, 1,   Cdc42↓, 1,   CEA↓, 1,   CLDN1↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 2,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MET↓, 1,   p‑MET↓, 1,   MMP2↓, 1,   N-cadherin↓, 3,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 2,   TumCA↓, 1,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 7,   Twist↓, 1,   Tyro3↓, 1,   Vim↑, 1,   vinculin↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 2,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

EGFR↑, 1,   p‑EGFR↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 2,   ICAM-1↓, 1,   IKKα↓, 1,   IL2↑, 1,   IL6↓, 1,   Inflam↑, 1,   p‑IκB↓, 1,   NF-kB↓, 6,   p‑p65↓, 1,   PD-1↓, 1,   PD-L1↓, 1,   PGE2↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

ABCG2↓, 1,   BioAv↑, 1,   ChemoSen↑, 4,   eff↓, 1,   eff↑, 2,   RadioS↑, 2,  

Clinical Biomarkers ⓘ

AR↓, 1,   CEA↓, 1,   EGFR↑, 1,   p‑EGFR↓, 1,   GutMicro↑, 1,   IL6↓, 1,   Ki-67↓, 1,   NSE↓, 1,   PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   Appetite↑, 1,   cachexia↓, 1,   chemoP↑, 2,   cognitive↑, 1,   OS↑, 1,   Pain↓, 1,   QoL↑, 1,   radioP↑, 1,   Sleep↑, 1,   toxicity↓, 2,  

Infection & Microbiome ⓘ

Bacteria↑, 1,  
Total Targets: 177

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 2,   GPx↑, 2,   GSH↑, 3,   GSR↑, 1,   GSTs↑, 2,   HO-1↑, 2,   lipid-P↓, 1,   NQO1↑, 1,   NRF2↑, 1,   PARK2↑, 1,   ROS↓, 1,   SOD↑, 2,   VDAC1↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,  

Cell Death ⓘ

p‑Akt↓, 1,   Apoptosis↓, 1,   Casp3↓, 1,  

Autophagy & Lysosomes ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑PI3K↓, 1,   PTEN↑, 1,  

Migration ⓘ

MMP13↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL10↑, 1,   IL1β↓, 2,   IL4↓, 1,   IL6↓, 1,   PGE2↓, 1,   TNF-α↓, 3,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 1,   neuroP↑, 1,   radioP↑, 1,   RenoP↑, 1,   toxicity↓, 1,  
Total Targets: 39

Scientific Paper Hit Count for: PI3K, Phosphatidylinositide-3-Kinases
2 5-fluorouracil
2 Magnolol
2 Thymoquinone
1 Astragalus
1 Apigenin (mainly Parsley)
1 Baicalein
1 almonertinib
1 Berberine
1 Biochanin A
1 Betulinic acid
1 Curcumin
1 Gallic acid
1 Garcinol
1 Cisplatin
1 Hydrogen Gas
1 Luteolin
1 Lycopene
1 Piperine
1 Quercetin
1 Resveratrol
1 Selenite (Sodium)
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:252  State#:1  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page